Prosecution Insights
Last updated: October 01, 2026

Examiner: SKELDING, ZACHARY S

Tech Center 1600 • Art Units: 1600 1644 1674

This examiner grants 60% of resolved cases

Analysis

Zachary S. Skelding has managed 834 resolved cases in Tech Center 1600. The examiner's allowance rate stands at 59.7 percent. This rate reflects the outcomes across a substantial volume of applications, providing a robust statistical foundation for prosecution planning in Art Unit 1600. Practitioners should note that this 59.7 percent allowance rate is a primary benchmark for success.

Direct engagement appears to be a productive tactic, as evidenced by an interview lift of 41.2 percent. This figure indicates that cases are significantly more likely to reach an allowance following a formal interview compared to the baseline. Practitioners should consider this 41.2 percent lift when deciding whether to request a meeting to discuss claim amendments or clarify technical points.

The median days to allowance for successful applications is 1331, indicating the typical timeline for reaching a favorable resolution. This duration of 1331 days helps in managing client expectations regarding the speed of the patent acquisition process in Tech Center 1600. By combining the volume of 834 resolved cases with the pendency data, practitioners can develop a comprehensive strategy for this art unit.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

59.7%
Allow Rate
At TC average
871
Total Applications
+41.2%
Interview Lift
1331
Avg Prosecution Days
Based on 834 resolved cases, 2023–2026

Rejection Statute Breakdown

2.8%
§101 Eligibility
14.5%
§102 Novelty
27.2%
§103 Obviousness
39.6%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18046865 METHODS FOR ASSAYING T-CELL DEPENDENT BISPECIFIC ANTIBODIES Final Rejection Genentech, Inc.
18477532 CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING THE TUMOR MICROENVIRONMENT Non-Final OA The General Hospital Corporation
18142129 GLYCOENGINEERING Non-Final OA The General Hospital Corporation
18184860 BCMA CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF Non-Final OA Novartis AG
18045946 LIQUID FORMULATION OF HUMANIZED ANTIBODY FOR TREATING IL-6-MEDIATED DISEASES Non-Final OA Bio-Thera Solutions, Ltd.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month